European Psychiatry - Volume 33 - March 2016

727 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S723
Conclusions Mechanisms of hyponatremia in patients with
schizophrenia are not well clarified; nevertheless, dopamine seems
to be the common link between psychogenic polydipsia and
schizophrenia.
Keywords Psychogenic Polydipsia; Hyponatremia;
Schizophrenia
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1171
Treatment with intramuscular
paliperidone palmitate in
schizoaffective disorder
L. Maroto Martin∗, P. Hervías Higueras
Hospital Doctor Rodríguez Lafora, Psiquiatría, Madrid, Spain
∗ Corresponding author.
Introduction Injectable formulations of long acting antipsychotic
are a valuable treatment option for patients with psychotic dis-
orders. Schizoaffective Disorder (SAD) is a complex disease; the
optimal treatment is not well established yet.
Objective Answer the question about the effectiveness offered
by intramuscular Paliperidone Palmitate in SAD versus other
injectable antipsychotics. Keywords: schizoaffective disorder;
paliperidone palmitate injection.
Methods A case report of a 35-year-old male diagnosed with
Schizoaffective Disorder six years ago and with personal history
of multiple manic decompensation after treatment discontinua-
tion. Throughout his life he has been treated with intramuscular
Risperidone 87.5mg (50 + 37.5) every 14 days, Olanzapine flas
20mg/day, Risperidone flas 3mg, Amisulpride 600mg/day, Val-
proic acid 1500mg/day Clonazepam 2mg/day and Lormetazepam
1mg. In the last admission one year ago, he started treatment
with intramuscular paliperidone palmitate up to 200mg a month.
Currently he receives a monthly dose of 100mg and concomitant
lithium 800mg/day.
Discussion The use of intramuscular paliperidone palmitate in
SAD and its effectiveness against other injectable antipsychotic is
discussed.
Conclusions The use of intramuscular paliperidone palmitate
appears to constitute an employment opportunity in the treatment
of intramuscular maintenance in SAD. It could be effective in stabi-
lizing episodes of acute exacerbation and remissions of psychotic,
manic and depressive symptoms.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1172
Characteristics of violent
schizophrenic inpatients
R. Masmoudi ∗, F. Charfeddine , L. Aribi , F. Smaoui , E. Elleuch ,
J. Aloulou , O. Amami
Hédi Chaker University Hospital, Psychiatry “B”, Sfax, Tunisia
∗ Corresponding author.
Introduction Hetero-aggressive behavior is a frequent reason for
psychiatric hospitalization in patients with schizophrenia.
Aim To describe the clinical and socio-demographic character-
istics of schizophrenic patients hospitalized following a violent
behavior.
Methods It was a cross-sectional and descriptive study. It was
conducted in 32 patients diagnosed with schizophrenia, and hos-
pitalized in the psychiatry department “B” at the Hedi Chaker
University Hospital of Sfax in Tunisia during the month of August
2014. The reason for hospitalization was hetero aggressiveness.
Results The average age of our patients was 36.19 years with a
male predominance (71.9%). Violent schizophrenic patients were
single (71.9%) and without occupation (68.8%). They have lived in
family in 81.3% of cases. They had a family history of psychiatric
disorders in 34.4% of cases, a criminal record in 25% of cases and
addictive behaviors in 71.9% of cases. Violent schizophrenics had
more than three psychiatric admissions in 50% of cases. They had
bad adherence to treatment (62.5%) and poor insight (87.5%). The
majority (90.6%) had a previous history of violent behavior. The
victim was a member of the patient’s family in 90%. At the time
of the incident, delusional syndrome was present in 78.1% of cases
and a mental automatism syndrome in 21.9% of cases.
Conclusion Violence in patients with schizophrenia depends on
several factors such as poor insight, medication non-adherence and
a past history of violence. It is essential to assess the risk of vio-
lent behavior and act on the associated factors in order to prevent
recurrence of violence.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1173
Battery of scales for comprehensive
assessment of social cognition,
neurocognition and motivation in
patients with schizophrenia
M. Minyaycheva ∗, K. Kiselnikova , O. Papsuev
Moscow Research Institute of Psychiatry, Outpatient Psychiatry and
Organization of Psychiatric Care, Moscow, Russia
∗ Corresponding author.
Introduction There has been a special interest in roles of neu-
rocognition, social cognition and motivation impairments in
patients with schizophrenia and possible approaches to remedi-
ating these deficits. Clinical practice lacks a comprehensive tool to
measure those deficits.
Objective To build a comprehensive assessment battery to mea-
sure neurocognitive, social cognitive and motivational deficits in
order to form targets for remediation programs and assess their
efficiency.
Aims Translation and adaptation for Russian speaking subjects
(if needed) of identified assessments upon authors’ agreement.
Methods By consensus decision of 5 professionals in the field
of clinical psychiatry, psychology and neuroscience a number of
assessments were selectedwith the following criteria: 1. Relevance
to domain assessed, 2. Appropriateness for Russian social context,
3. Reference rates in scientific papers, 4. Time consumed by each
assessment.
Results Six measures reflecting main domains (neurocognition,
Theory of Mind, attributional style, social perception, emotion pro-
cessing, motivation) were selected: 1. BACS (Brief Assessment of
Cognition in Schizophrenia) (R.S. Keefe et al., 2008), 2. Hinting
Task (R. Corcoran 1995), 3. AIHQ (Ambiguous Intentions Hostility
Questionnaire) (D.R. Combs et al., 2007), 4. RAD–15 (Relationships
Across Domains) (M. Sergi et al., 2004), 5. Ekman–60 (P. Ekman
et al., 1976), 6. AES (Apathy Evaluation Scale) (R.S. Marin et al.,
1991).
Conclusions The battery built encompasses all targeted domains
of neurocognition, social cognition andmotivation. Time consumed
by the battery estimates 130 ±15minutes, which is appropriate
for clinical practice in a rehabilitation centre. Future research will
focus on patients profiling and shaping of rehabilitation programs
accordingly.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.